Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine

NEW HAVEN, Conn., Nov. 16, 2017 -- (Healthcare Sales & Marketing Network) -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced that it is completing enrollment today in the first of its two registrational Phase 3 clinical trials, Study B... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, rimegepant, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news